Locate Available Clinical Trials
To view available Clinical Trial information choose from the list on the right or search using the fields below.
trial #
trial description
- Alliance A091605
-
The purpose of this study is to compare any good and bad effects of using radiation along with an immunotherapy treatment [MK-3475 (pembrolizumab)] compared with MK-3475 (pembrolizumab) alone. The addition of radiation to the usual immunotherapy may shrink your Merkle Cell cancer and possibly increase the effect of immunotherapy in other parts of the body. Combining radiation with immunotherapy could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the radiation with immunotherapy approach should increase the time it takes until the cancer grows compared to the usual approach. Radiation is a standard treatment for cancer. The immunotherapy drug MK-3475 (pembrolizumab) is already FDA-approved for use in several types of cancer (lung, bladder, kidney cancers as well as melanoma) but for your type of cancer it is considered research.
